Rituximab can be used in membranous nephropathy, but it should be evaluated by a doctor before use. The development of membranous nephropathy is related to the deposition of immune complexes on the glomerular epithelial side, antibody-mediated, resulting in the destruction of the glomerular filtration barrier and damage to the podocytes. Rituximab reduces the production of immune complexes associated with B cells by initiating an immune response that mediates B cell lysis, thereby reducing complex deposition and improving membranous nephropathy. Although rituximab can be used in membranous nephropathy, not all patients can use this drug, for example, those who are allergic to the components of the drug and the mouse protein need to be prohibited, so it should be combined with the patient’s condition, after a detailed assessment by the doctor, can be used, and the clinic is often used in conjunction with glucocorticoids and cytotoxic drugs. Rituximab may cause tinnitus and earache, weight loss, anemia, abnormal sensation, infection, gastrointestinal discomfort, rash and itching and other adverse reactions. Very few patients may even have serious fatal reactions during the infusion of the drug, so it is important to keep the patient under constant observation. For membranous nephropathy, Rituximab, as a prescription drug, must be used under the direction of a doctor.